Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4021178 | 0.99 | SLC6A2 (0.43) | SLC6A2SLC6A3MCHR1SIGMAR1SLC6A4 | |
| SCHEMBL8112597 | 0.96 | SLC6A2 (0.43) | SLC6A2SLC6A3MCHR1SIGMAR1SLC6A4 | |
| SCHEMBL27499030 | 0.86 | SLC22A1 (0.47) | SLC6A2SLC6A4 | |
| SCHEMBL6210054 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4LMNAHTT | |
| SCHEMBL6660824 | 0.78 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4LMNAHTT | |
| SCHEMBL7629979 | 0.77 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4CYP2D6HTR2C | |
| SCHEMBL8105071 | 0.76 | SLC6A2 (0.42) | SLC6A2SLC6A3SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL7164271 | 0.75 | CHRM2 (0.54) | SLC6A2SLC6A3SIGMAR1LMNAHTT | |
| SCHEMBL28838197 | 0.74 | AKR1C1 (0.45) | SLC6A2SLC6A3SLC6A4CYP2D6HTR2C | |
| Hydrochloric Acid SCHEMBL4106135 | 0.74 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441706-A2 | ANTIMUSCARINIC AEROSOL | Pharmacia & Upjohn Company (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030144352-A1 | Antimuscarinic aerosol | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | claimed |
| EP-1330241-A2 | USE OF TOLTERODINE TO TREAT ASTHMA | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2003039464-A2 | ANTIMUSCARINIC AEROSOL | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| US-6538035-B2 | And treatment of Chronic Obstructive Pulmonary Disease and allergic rhinitis | PHARMACIA & UPJOHN COMPANY | 2003-03-25 | — | — | US | claimed |
| US-20020161054-A1 | Use of tolterodine to treat asthma | PHARMACIA & UPJOHN COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002034245-A2 | USE OF TOLTERODINE TO TREAT ASTHMA | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | WO | claimed |
| EP-1461306-B1 | QUATERNARY AMMONIUM COMPOUNDS AND THEIR USE AS ANTIMUSCARINIC AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7439397-B2 | reacting methyl bromide and 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol; formation of (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide; asthma, chronic obstructive pulmonary disorder, allergic and infectious rhinitis | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7291648-B2 | 3,3-diphenylpropylamines useful in therapy | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060281812-A1 | NOVEL 3,3-diphenylpropylamines USEFUL IN THERAPY | PHARMACIA & UPJOHN COMPANY LLC | 2006-12-14 | — | — | US | disclosed |
| US-7119121-B2 | 3,3-diphenylpropylamines useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-7005449-B2 | Tolterodine salts | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-6538035-B2 | And treatment of Chronic Obstructive Pulmonary Disease and allergic rhinitis | PHARMACIA & UPJOHN COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-6538035-B2 | And treatment of Chronic Obstructive Pulmonary Disease and allergic rhinitis | PHARMACIA & UPJOHN COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-20020161054-A1 | Use of tolterodine to treat asthma | PHARMACIA & UPJOHN COMPANY | 2002-10-31 | — | — | US | disclosed |
| US-20020161054-A1 | Use of tolterodine to treat asthma | PHARMACIA & UPJOHN COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002034245-A2 | USE OF TOLTERODINE TO TREAT ASTHMA | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002034245-A2 | USE OF TOLTERODINE TO TREAT ASTHMA | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144352-A1 | Antimuscarinic aerosol | CHRM3, CHRM1, CHRM5 | SLC6A2 151/4885SLC6A3 243/4885MCHR1 596/4885 |
| US-20060281812-A1 | NOVEL 3,3-diphenylpropylamines USEFUL IN THERAPY | QDPR, HRH3, SLC7A1 | SLC6A2 51/4885SLC6A3 4/4885MCHR1 1577/4885 |
| US-20020161054-A1 | Use of tolterodine to treat asthma | THOP1, ADRB2, HRH2 | SLC6A2 754/4885SLC6A3 553/4885MCHR1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.